{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T11:39:52Z","timestamp":1779881992091,"version":"3.53.1"},"reference-count":35,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2007,10,6]],"date-time":"2007-10-06T00:00:00Z","timestamp":1191628800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Aliment Pharmacol Ther"],"published-print":{"date-parts":[[2008,1]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p><jats:bold>Background\u2002<\/jats:bold> Crohn\u2019s disease is characterised by recurrent flare\u2010ups alternating with periods of remission. A number of interventions are currently used in clinical practice to try and maintain remission in Crohn\u2019s disease but the evidence base for some of them may be questionable.<\/jats:p><jats:p><jats:bold>Aim\u2002<\/jats:bold> To review the available evidence on interventions, which are currently used to maintain remission in Crohn\u2019s disease.<\/jats:p><jats:p><jats:bold>Methods\u2002<\/jats:bold> The Cochrane Library and Medline (Pubmed) were searched for level 1 evidence on specific interventions. Search terms included \u2018Crohn\u2019s disease or synonyms\u2019, \u2018remission or synonyms\u2019 and the names of specific interventions.<\/jats:p><jats:p><jats:bold>Results\u2002<\/jats:bold> Azathioprine, infliximab and adalimumab are effective at maintaining remission in Crohn\u2019s disease. Natalizumab is also effective, but there are concerns about its potential association with progressive multifocal leukoencephalopathy. Long\u2010term enteral nutritional supplementation, enteric\u2010coated omega\u20103 fatty acids and intramuscular methotrexate may also be effective but the evidence for these is based on relatively small studies. The available evidence does not support the use of oral 5\u2010aminosalicylates agents, corticosteroids, anti\u2010mycobacterial agents, probiotics or ciclosporin as maintenance therapy in Crohn\u2019s disease.<\/jats:p><jats:p><jats:bold>Conclusion\u2002<\/jats:bold> A better understanding of the evidence base of existing interventions could result in the use of treatments, which are more likely to lead to improved patient outcomes.<\/jats:p>","DOI":"10.1111\/j.1365-2036.2007.03536.x","type":"journal-article","created":{"date-parts":[[2010,7,23]],"date-time":"2010-07-23T13:56:51Z","timestamp":1279893411000},"page":"11-18","source":"Crossref","is-referenced-by-count":35,"title":["Review article: the evidence base for interventions used to maintain remission in Crohn\u2019s disease"],"prefix":"10.1111","volume":"27","author":[{"given":"A. K.","family":"AKOBENG","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2007,10,6]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"publisher","DOI":"10.1186\/1471-230X-2-1"},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1463-1318.2003.00407.x"},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.323.7308.334"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD003715.pub2"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.1002\/ibd.20074"},{"key":"e_1_2_6_7_2","first-page":"A","article-title":"Risk factors associated with small bowel adenocarcinoma in Crohn\u2019s disease: a case\u2010control study","volume":"132","author":"Piton G","year":"2007","journal-title":"Gastroenterology"},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD000067"},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD000301"},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD002913"},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.2005.41992.x"},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD000299"},{"key":"e_1_2_6_13_2","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2007.03.031"},{"key":"e_1_2_6_14_2","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD004826.pub2"},{"key":"e_1_2_6_15_2","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD005984.pub2"},{"key":"e_1_2_6_16_2","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD006320.pub2"},{"key":"e_1_2_6_17_2","first-page":"1724","article-title":"Methotrexate in Crohn\u2019s disease: results of a randomized, double\u2010blind, placebo\u2010controlled trial","volume":"46","author":"Arora S","year":"1999","journal-title":"Hepatogastroenterology"},{"key":"e_1_2_6_18_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200006013422202"},{"key":"e_1_2_6_19_2","doi-asserted-by":"publisher","DOI":"10.1136\/gut.2005.081950b"},{"key":"e_1_2_6_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0016-5085(99)70332-X"},{"key":"e_1_2_6_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(02)08512-4"},{"key":"e_1_2_6_22_2","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2006.12.003"},{"key":"e_1_2_6_23_2","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2006.02.014"},{"key":"e_1_2_6_24_2","doi-asserted-by":"publisher","DOI":"10.1097\/00042737-200601000-00003"},{"key":"e_1_2_6_25_2","doi-asserted-by":"publisher","DOI":"10.1097\/MPG.0b013e31802f6424"},{"key":"e_1_2_6_26_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2006.02786.x"},{"key":"e_1_2_6_27_2","doi-asserted-by":"publisher","DOI":"10.1002\/ibd.20169"},{"key":"e_1_2_6_28_2","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2006.11.041"},{"key":"e_1_2_6_29_2","doi-asserted-by":"publisher","DOI":"10.1136\/gut.2006.106781"},{"key":"e_1_2_6_30_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa043335"},{"key":"e_1_2_6_31_2","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD006097.pub2"},{"key":"e_1_2_6_32_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa062897"},{"key":"e_1_2_6_33_2","doi-asserted-by":"publisher","DOI":"10.1016\/0016-5085(95)90384-4"},{"key":"e_1_2_6_34_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bpg.2003.12.003"},{"key":"e_1_2_6_35_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(07)60750-8"},{"key":"e_1_2_6_36_2","doi-asserted-by":"publisher","DOI":"10.1002\/ibd.20220"}],"container-title":["Alimentary Pharmacology &amp; Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2036.2007.03536.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1365-2036.2007.03536.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,13]],"date-time":"2023-10-13T12:41:56Z","timestamp":1697200916000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1365-2036.2007.03536.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,10,6]]},"references-count":35,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2008,1]]}},"alternative-id":["10.1111\/j.1365-2036.2007.03536.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1365-2036.2007.03536.x","archive":["Portico"],"relation":{},"ISSN":["0269-2813","1365-2036"],"issn-type":[{"value":"0269-2813","type":"print"},{"value":"1365-2036","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,10,6]]}}}